Russia's FSB says minor detained over park attack threat after US tip-off Reuters
Why PRFX Stock dropped -3.86% Today — RQD Quant Desk Flash
PRF Technologies Ltd. (PRFX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, PRF Technologies Ltd. (NASDAQ: PRFX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.75 (-3.86% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRFX ranks #687 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PRFX compare to HCWB and SBFM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, HCWB (HCW Biologics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PRFX?
▼
Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue, -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a PRFX Turnaround Squeeze
While PRFX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.90) and Max Pain ($0.79) forces dealer call-delta covering toward $8.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why PRFX Stock dropped -3.86% Today — RQD Quant Desk Flash
PRF Technologies Ltd. (PRFX) dropped -3.86% to $0.75, trading at 2% of its 52-week range ($0.69 – $7.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.69 – $7.95) with RSI-14 at 36.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 0% gross margin and $0 annual free cash flow.
Oil slips more than 1% as talks continue on ending Iran war Reuters
Nine people dead in Learjet crash in south Florida, officials say Reuters
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
The market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Haley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
Israeli strikes kill eight people in Gaza - medics say Reuters
Iran, Qatari mediators hold third day of talks to end US-Iran war Reuters
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRFX)
- ✓Walkthrough of PRFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
PRFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PRFX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PRFX. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRFX)
1. Head-to-Head Health Care Peer Comparison (PRFX vs. HCWB, SBFM, APVO, SILO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, PRF Technologies Ltd. (PRFX) ranks #687 by composite RQD confidence (39/100, grade D-) and #985 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, PRFX leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PRFX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRFX
ACTIVE
PRF Technologies Ltd. | D- | 39/100 | — | -30.0% | -35.0% | -3.86% | $2.6M | Benchmark Subject |
| HCWB HCW Biologics Inc. | E | 27/100 | — | 20.0% | -35.0% | -3.28% | $2.6M | /hcwb-vs-prfx → |
| SBFM Sunshine Biopharma Inc. | D | 44/100 | — | 33.8% | -21.4% | +7.07% | $2.5M | /sbfm-vs-prfx → |
| APVO Aptevo Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +4.62% | $2.5M | /apvo-vs-prfx → |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-prfx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801834In its most recent audited fiscal period (FY2025, filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported GAAP revenue of $17.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$5.0M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (+68.7% YoY). On the balance sheet, PRFX closed FY2025 with $12.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $17.0K | -$5.0M | -$4.0M | -$4.0M | $12.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$14.6M | -$12.6M | -$12.6M | $4.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$9.3M | -$6.7M | -$6.7M | — | — |
3. PRFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, PRF Technologies Ltd. (NASDAQ: PRFX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.75 (-3.86% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRFX ranks #687 in composite RQD confidence.
How does PRFX compare to HCWB and SBFM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, HCWB (HCW Biologics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRFX?
Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue, -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRFX trading relative to its 50-day, 200-day, and 52-week technical levels?
PRFX last traded at $0.75 (-3.86% on volume of 30,043 shares), positioning the stock -16.67% below its 50-day simple moving average ($0.90) and -59.02% below its 200-day simple moving average ($1.83). Across its 52-week range of $0.69 to $7.95, PRFX sits at the 0.8% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.84).
PRFX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PRFX stock moving today?
Why PRFX Stock dropped -3.86% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.